Фото: Peopleimages / Getty Images
一边是连续六年累计亏损超10亿元、但营收为零的“吞金兽”体质，一边是逼近40亿元的估值与港股IPO的目标，浙江医药这套“增资稀释+分拆上市”的组合拳，既是为新码生物的研发与商业化输血，也是一场围绕ADC（抗体偶联药物）管线价值的战略布局。
，详情可参考PDF资料
enables digital AI agents to take on increasingly challenging tasks
The emergency request was granted on Monday and the decision was made along party lines, with the three liberal justices dissenting.